Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping.

John Hallick,Anne-Marie Baird,Gerald Falchook,Xiuning Le,David Hong, Santiago Viteri,Jo Raskin,Niels Reinmuth,Soetkin Vlassak, Mihaela Militaru,Paul K Paik

Future oncology (London, England)（2023）

引用 0|浏览26

暂无评分

摘要

In the studies summarized here, people with exon 14 skipping NSCLC who took tepotinib had their tumor growth stopped or their tumor shrunk for a period of time, and they mostly experienced side effects that they could tolerate. : NCT01014936 (tepotinib first-in-human), NCT02864992 (VISION), NCT03940703 (INSIGHT 2) (ClinicalTrials.gov).

查看译文

关键词

MET exon skipping,NSCLC,lay summary,non small cell lung cancer,plain language summary,targeted therapy,tepotinib,tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要